Skip to main content
Equibles
DMAC logo

DMAC · DiaMedica Therapeutics Inc.

Track DMAC — free

Use DMAC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DMAC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.68 -0.07 (-1.04%) At close · Aug 14
Market Cap
$360.22M
Shares
53.93M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.68 Open$6.74 Day$6.55–6.79 52W close$5.30–9.39 Avg vol 30d187K Short int5.2M · 9.6% float · 27.4d Short vol51% Last earningsAug 11, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −7%
      below
      Price vs 50-day avg +0%
      above
      RSI (14) 48
      neutral
      MACD trend Positive
      52-week position 34%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −8%
      trailing
      6-month return −20%
      trailing
      YTD return −16%
      this year
      Relative strength −33%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $7 › 200d $7 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +12 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      9.65% of float · ▲ +1.8% MoM · 27.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      88 holders — mid 3-yr range
      Squeeze score 78
      high risk · 0–100
      Fundamentals
      Fair
      Free cash flow $-29.1M
      Balance sheet $15.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 59%
      annualized · 1-yr
      Max drawdown −43%
      past year
      ATR 5.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −7% Bearish
      Price vs 50-day avg
      +0% Bullish
      RSI (14)
      48 Neutral
      MACD trend
      Positive Bullish
      52-week position
      34% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $7 › 200d $7 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +12 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      9.65% of float · ▲ +1.8% MoM · 27.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      88 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $5 Now $7 · 34% Range high $9
      vs 200-day avg -7% vs 50-day avg +0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Activated sites 70 Q2 2026 —
      Mean reduction in diastolic blood pressure (DBP) in combined final, highest-dose cohorts (cohort 17 Part 1a topline results —
      Mean reduction in systolic blood pressure (SBP) in combined final, highest-dose cohorts (cohort 29.1 Part 1a topline results —
      Phase 2/3 ReMEDy2 trial enrollment (percent of 200 participants required for interim analysis) 85% Q2 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      DMAC
      DiaMedica Therapeutics Inc.
      this stock
      		$360.22M -16.1% — — 9.6%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      88
      % held
      23.1%
      Net QoQ
      +700.0K sh
      Top holder
      COOPERMAN LEON G
      Held Float
      View
      Held by Funds
      Fund positions
      77
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      5.2M
      Days to cover
      27.4d
      Change
      +92.4K sh
      View
      Short Volume
      Short vol %
      51%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.1K
      Value
      $41.1K
      As of
      Jul 8, 2026
      View
      Off-Exchange
      Off-exchange %
      34.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Net income (FY)
      $-32.8M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 10, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $109.5K
      Shares
      39.7K
      Filed
      Jul 2, 2024
      View
      Exempt Offerings
      Offering
      $30.1M
      Filed
      Jul 25, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      DMAC -1.0% -8.5% -19.6% +5.4% -16.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -1.4% -12.9% -33.4% +1.4% -29.9%
      Key facts CIK 1401040 CUSIP 25253X207 13F (30d) 84 filings 84 filers Visit website

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)